• Home
  • Search Results
  • Accelerated telomere reduction and hepatocyte senescence in tolerated human liver allografts.

Accelerated telomere reduction and hepatocyte senescence in tolerated human liver allografts.

Transplant immunology (2014-07-06)
Wulamujiang Aini, Aya Miyagawa-Hayashino, Munetaka Ozeki, Salah Adeeb, Masahiro Hirata, Keiji Tamaki, Shinji Uemoto, Hironori Haga
ABSTRACT

In living donor liver transplantation, the biological organ age of the donated allograft is unknown in young patients who receive grafts from older donors. Few studies have focused on the effects of aging on allografts in the state of tolerance. The purpose of this study was to assess the biological organ age of liver grafts. In 20 tolerated allografts over a 10-year post-transplant follow-up period, the relative telomere lengths were measured by multiplex quantitative polymerase chain reaction, and hepatocyte nuclear size and cell cycle phase markers were determined by immunohistochemistry. The results were compared with the same measurements that had been obtained prior to transplantation in the recipients' pre-implantation donor livers. Tolerance was defined strictly as a condition in which the allograft functioned normally and showed normal histology without any histological signs of rejection, fibrosis or inflammation in the absence of immunosuppression. First, telomere length correlated with chronological donor age (n=41). Accelerated telomere reduction was seen in tolerated grafts compared with the predicted telomere length of each allograft calculated from the regression line of donor livers. Tolerated grafts were associated with higher hepatocyte p21 expression and greater nuclear area than in the donor livers prior to transplantation. These findings suggest that allografts age more rapidly than in the normal population, and that grafts may reach the limit of proliferative capacity even in the state of tolerance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-KRAS antibody produced in mouse, clone 3B10-2F2, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-KRAS antibody produced in mouse, clone 4F3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-KRAS antibody, Mouse monoclonal, clone KRAS-A582, purified from hybridoma cell culture
Sigma-Aldrich
Anti-KRAS antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-NSG1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-D4S234E antibody produced in mouse, clone 1C3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-KRAS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-KRAS antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-c-K-Ras antibody produced in mouse, clone 234-4.2, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-NS3 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution